Skip to main content
Premium Trial:

Request an Annual Quote

Seqster, Antidote Technologies Partner on Clinical Trial Patient Management

NEW YORK — Digital health firms Seqster and Antidote Technologies said Monday that they have agreed to combine certain of their technologies to improve patient identification and enrollment for clinical trials.

Under the terms of the deal, the companies will integrate Seqster's Operating System — which is designed to manage clinical trial data around patient recruitment, retention, and health — with Antidote's patient screening and support services.

Seqster's platform aggregates and harmonizes patient clinical data, including genomic data, from multiple sources including health records and wearables.

"This partnership empowers us to accelerate patient recruitment while providing a comprehensive, real-time view of study participant health data," Seqster Cofounder and CEO Ardy Arianpour said in a statement.

Financial and other terms were not disclosed.

In mid-2022, San Diego-based Seqster began working with Boehringer Ingelheim to create a data portal for patients and researchers in clinical trials. That same year, North Miami Beach, Florida-based Antidote and OneStudyTeam struck a deal to join their technologies to offer a patient referral management toll for clinical trial recruitment.